Drug intelligence / Profile preview

CVI-2742

Development stage: Unknown
Lead developer: CVI Pharmaceuticals (Shanghai) Co Ltd
Modality: Small Molecules
Administration: Oral

Overview

CVI-2742 is a highly potent, liver-directed, second-generation selective agonist of thyroid hormone receptor beta (THR-β), developed for the treatment of nonalcoholic steatohepatitis (NASH) and hyperlipidemias. It is designed for oral administration, demonstrates rapid and selective accumulation in the liver with minimal distribution to other tissues, and shows a broad safety window and high efficacy in preclinical models. CVI-2742 acts as a full agonist at THR-β, leading to improved lipid metabolism and a reduction in serum cholesterol and LDL-C[1][2][4].

Targets

THRA (Thyroid hormone receptor alpha)THRB (Thyroid hormone receptor beta)

Beyond the preview

Go deeper on CVI-2742.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CVI-2742.

Explore the full profile